Showing posts with label Pieter Droppert. Show all posts
Showing posts with label Pieter Droppert. Show all posts

June 3, 2013

$PVCT Blog Reader Cracks Me Up

Been reading your blog for a year now. Informative, well thought out, interesting, amusing, irritating. It's everything it should be. Am holding 50k shares-bought cheap and losing it all will not change my life. Having said that, any rise in price will be a nice surprise. I intend to ride the horse until he either dies or makes it back to the stable. One final thought. You are one optimistic, glass half full guy.
Classic. Thank you.

ASCO 2013: Overcoming Resistance to Cancer Drug Therapy: "Dr. Charles Sawyers, MD, current President of the American Association for Cancer Research (AACR) on June 2nd 2013, received the American Society of Clinical Oncology (ASCO) 2013 Science of Oncology Award and subsequently gave a plenary lecture on overcoming resistance to cancer drug therapy."

The author of the above Storify, Pieter Droppert, wrote that Dr. Sawyers said "...drug resistance is universal. It represents one of the key challenges in cancer treatment" and that "...we need to combination therapy faster in order to overcome cancer drug resistance."

Moffit's Dr. Jeffrey Weber's interest in and excitement over PV-10 is much clearer to me, only once I better understood (realized) Dr. Sawyer's message, which I repeat by writing that the heart of the matter to researchers and clinicians is utilizing combination therapy as a way to overcome drug resistance.

Combination therapy is very important to Moffitt Cancer Center and Dr. Weber because, presumably, they believe it is the key to addressing and potentially overcoming drug resistance.

PV-10 is very important to Dr. Weber et al. in no small part because Dr. Weber and his Moffitt colleagues believe they can overcome resistance to cancer drug therapy with PV-10, due to this drug's unique mechanism of action and orthogonality with other drugs (in addition to its efficacy, safety, and beneficial features of being both a targeted therapy and an immunotherapy).

February 26, 2013

$PVCT: @MaverickNY: TLS, what is it and why is it important to cancer research

Around mid-February a reader of this blog asked about Tumor Lysis Syndrome ("TLS") in the context of PV-10. He forwarded me the link to Dr. Sally Church's blog's article about TLS. This topic was raised because AbbVie suspended 5 clinical studies for experimental leukemia and lymphoma medicine because patients died from tumor lysis syndrome ("TLS").

Pieter Droppert wrote:
Source
Dr. Church wrote:

I do not think this is an issue for PV-10, but I learned quite a lot by exploring the topic and delving further into what makes Provectus' drug unique. The generation of too much necrotic tissue at one time is not good. It is important to manage tumor burden with the ablation of PV-10. Thus far, debulking was taken care of before patients were treated with PV-10 through surgical excision. As PV-10 is used in different stages of disease, however, physicians should take a balanced approach, making sure the entire tumor burden of the patient is properly treated. For example, a patient may have some surgical excision depending on tumor size, and then be treated with PV-10 for the remainder of the disease. Or, his or her tumor burden could be treated over a period of time with PV-10.

One key to PV-10's unique ability to very effectively treat local and distant cancer lies in the intratumoral delivery of the drug. This intratumoral route helps generate the remote response or bystander effect.

Systemic delivery, according to Craig, is what's wrong with chemotherapy. This route creates bad side effects, generates poor efficacy, and kills anti-tumor immunity, induces tolerance or shuts it off entirely.

Provectus has been careful about the size of tumor that would or should addressed by PV-10 because of the very issue of overwhelming a patient with dead tissue, which is a topic well known in medical literature (including, for example, literature related to radiofrequency ablation). Dosing, for example, plays an important role. A successful approach requires understanding several factors, among them the amount of necrotic tissue generated by PV-10 in different situations and under different scenarios, toxicity, etc. How much tumor you kill immediately versus over time not only influences dosing, but it also influences treatment approach.